Marit Sjo Lorentzen

Chief Operating Officer bei ARCTICZYMES TECHNOLOGIES ASA

Vermögen: 55 306 $ am 31.03.2024

56 Jahre

Health Technology

Consumer Services

Profil

Marit Sjo Lorentzen is currently the Director at Biotec BetaGlucans AS and the Vice President-Operations at ArcticZymes Technologies ASA. She has an undergraduate degree from the University of Tromso.

Bekannte Unternehmensbeteiligungen

Unternehmen	Datum	Anzahl der Aktien	Bewertung	Datum der Bewertung
ARCTICZYMES TECHNOLOGIES ASA 0,04%	31.03.2023	20 331 ( 0,04% )	55 306 $	31.03.2024

Aktive Positionen von Marit Sjo Lorentzen

Unternehmen	Position	Beginn
ARCTICZYMES TECHNOLOGIES ASA	Chief Operating Officer	-
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Director/Board Member	-

Alle aktiven Positionen von Marit Sjo Lorentzen

Ausbildung von Marit Sjo Lorentzen

University of Tromso

Undergraduate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Marit Sjo Lorentzen im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen	1
ARCTICZYMES TECHNOLOGIES ASA	Health Technology

Private Unternehmen	1
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Health Technology